Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008676

SCHEMBL1008676

SCHEMBL1008676

O=C(O)C(CC1CCCC1)n1ncc(Oc2cccc3ncccc23)cc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 1/20 0.39
▸ GCK P35557 3/20 0.37
▸ ABCB1 P08183 1/20 0.37
▸ F12 P00748 1/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ GPR132 Q9UNW8 1/20 0.35
▸ HTR1A P08908 4/20 0.35
▸ P2RX7 Q99572 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ EGLN3 Q9H6Z9 1/20 0.34
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ CASP8 Q14790 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008789 0.87 KCNH2 (0.40) GPBAR1GCKGPR132LMNAKMT2A
SCHEMBL1008568 0.87 SIRT2 (0.41) GPBAR1F12LMNAKMT2A
SCHEMBL1008902 0.86 GCK (0.38) GCKGPR132
SCHEMBL1009338 0.84 NR2F2 (0.39) GPBAR1PDGFRBGPR132HCRTR1HCRTR2
SCHEMBL1008584 0.82 HIF1A (0.36) GPBAR1GCKP2RX7KMT2A
SCHEMBL1058556 0.82 GPBAR1 (0.38) GPBAR1PDGFRBHTR1A
SCHEMBL1008126 0.81 EGLN1 (0.42) GPBAR1EGLN1
SCHEMBL1008265 0.81 FFAR1 (0.40) EGLN1KMT2A
SCHEMBL1008741 0.81 LPAR1 (0.39) HCRTR1HCRTR2KMT2A
SCHEMBL1007288 0.81 LPAR1 (0.41) EGLN1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK GPBAR1 2679/4885GCK 1/4885ABCB1 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.